Preventive and therapeutic effects of imatinib in Wistar-Kyoto rats with anti-glomerular basement membrane glomerulonephritis (Q46109613)

19 December 2017

title

Preventive and therapeutic effects of imatinib in Wistar-Kyoto rats with anti-glomerular basement membrane glomerulonephritis (English)

1 reference

19 December 2017

main subject

imatinib

1 reference

ChEBI release 2020-05-28

1 reference

5

Tadao Akizawa

1 reference

19 December 2017

author name string

Masayuki Iyoda

1

1 reference

19 December 2017

Takanori Shibata

2

1 reference

19 December 2017

Mio Kawaguchi

3

1 reference

19 December 2017

Toshimitsu Yamaoka

4

1 reference

19 December 2017

language of work or name

English

0 references

publication date

25 February 2009

1 reference

19 December 2017

published in

Kidney International

1 reference

19 December 2017

volume

75

1 reference

19 December 2017

issue

10

1 reference

19 December 2017

page(s)

1060-1070

1 reference

19 December 2017

https://scigraph.springernature.com/pub.10.1038/ki.2009.43

exact match

0 references

cites work

Important role for macrophages in induction of crescentic anti-GBM glomerulonephritis in WKY rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.43

7 January 2021

Depletion of CD8 positive cells in nephrotoxic serum nephritis of WKY rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.43

7 January 2021

Cytokines and cell cycle regulation in the fibrous progression of crescent formation in antiglomerular basement membrane nephritis of WKY rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.43

7 January 2021

Mechanisms and kinetics of Bowman's epithelial-myofibroblast transdifferentiation in the formation of glomerular crescents

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.43

7 January 2021

Connective tissue growth factor participates in scar formation of crescentic glomerulonephritis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.43

7 January 2021

Pharmacology of imatinib (STI571).

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.43

7 January 2021

PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.43

7 January 2021

Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: tyrosine kinase inhibitors as a potential therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.43

7 January 2021

Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.43

7 January 2021

Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.43

7 January 2021

Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.43

7 January 2021

Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.43

7 January 2021

Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.43

7 January 2021

Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.43

7 January 2021

Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.43

7 January 2021

Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.43

7 January 2021

Imatinib mesylate inhibits antigen-specific memory CD8 T cell responses in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.43

7 January 2021

Tubules are the major site of M-CSF production in experimental kidney disease: correlation with local macrophage proliferation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.43

7 January 2021

Imatinib suppresses cryoglobulinemia and secondary membranoproliferative glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.43

7 January 2021

Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.43

7 January 2021

cDNA cloning and expression of the human A-type platelet-derived growth factor (PDGF) receptor establishes structural similarity to the B-type PDGF receptor

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.43

7 January 2021

Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.43

7 January 2021

Imatinib inhibits the functional capacity of cultured human monocytes.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.43

7 January 2021

Intervention of crescentic glomerulonephritis by antibodies to monocyte chemotactic and activating factor (MCAF/MCP-1)

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.43

7 January 2021

Mechanisms of T cell-induced glomerular injury in anti-glomerular basement membrane (GBM) glomerulonephritis in rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.43

7 January 2021

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.43

7 January 2021

High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.43

7 January 2021

Aggravation of rat nephrotoxic serum nephritis by anti-myeloperoxidase antibodies

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.43

7 January 2021

Blockade of TGF-beta action ameliorates renal dysfunction and histologic progression in anti-GBM nephritis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.43

7 January 2021

RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.43

7 January 2021

The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.43

7 January 2021

Identifiers

DOI

10.1038/KI.2009.43

1 reference

19 December 2017

PubMed ID

19242505

1 reference

19 December 2017